Nov 9, 2021
With the licensing agreement between Treeway and Ferrer in place, FNP122 (formerly TW001) has now entered clinical stage phase III with the initiation of the ADORE study (ALS Deceleration study with Oral Edaravone). In a large-scale double-blind placebo-controlled...
Nov 9, 2021
Barcelona, November 9th, 2021 – Ferrer, an international pharmaceutical company focused on neurological disorders and pulmonary vascular and interstitial lung diseases, has today announced the next major milestone in its mission to develop transformative therapies...
Oct 20, 2021
Barcelona and Tilburg, 20 October 2021 – Today, Ferrer, an international pharmaceutical company focused on pulmonary vascular and interstitial lung diseases and neurological disorders, and Treeway, a clinical-stage biotechnology company, announced they have entered...
Apr 10, 2019
On Thursday April 18, Treeway’s CEO Inez de Greef is a speaker at the Rare Diseases Symposium. The second edition of the Rare Disease Symposium, organized by HollandBIO, is about challenging the status quo and the development of orphan drugs. Inez will talk about...
May 29, 2018
–Study suggests that novel oral formulation of edaravone improves bioavailability while remaining well tolerated– Rotterdam, The Netherlands, May 29th2018 – Treeway, a biotech company developing therapies against amyotrophic lateral sclerosis (ALS), today announced...
